CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Gollner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Muller-Tidow C
Int J Cancer. 2022 Apr 1;150(7):1141-1155. doi: 10.1002/ijc.33865. Epub 2021 Nov 23.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
No plasmids are currently publicly available from Addgene for this article.